| 000 | 01137 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250515114312.0 | ||
| 264 | 0 | _c20080623 | |
| 008 | 200806s 0 0 eng d | ||
| 022 | _a1476-5551 | ||
| 024 | 7 |
_a10.1038/leu.2008.94 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCarella, A M | |
| 245 | 0 | 0 |
_aInterferon-alpha is able to maintain complete molecular remission induced by imatinib after its discontinuation. _h[electronic resource] |
| 260 |
_bLeukemia _cMay 2008 |
||
| 300 |
_a1090-1 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Letter | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImatinib Mesylate |
| 650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPiperazines _xtherapeutic use |
| 650 | 0 | 4 |
_aPyrimidines _xtherapeutic use |
| 650 | 0 | 4 | _aRemission Induction |
| 773 | 0 |
_tLeukemia _gvol. 22 _gno. 5 _gp. 1090-1 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/leu.2008.94 _zAvailable from publisher's website |
| 999 |
_c17885076 _d17885076 |
||